Microcoaxial torsional phaco method of choice

Article

The vast majority of ophthalmologists are going to become convinced that 2.2 mm microcoaxial surgery with Ozil (Alcon) phaco must be the method of choice for both surgeons and patients said Dr Robert Osher.

The vast majority of ophthalmologists are going to become convinced that 2.2 mm microcoaxial surgery with Ozil (Alcon) phaco must be the method of choice for both surgeons and patients said Dr Robert Osher.

Dr Osher, who is working with a new proprietary Ozil programme, told delegates that there is very little turbulence with the Ozil. "There is an enormous amount of efficiency and it is thermal protected. Not only is there additional thermal protection for the sleeve but, because of the slope of the tip, there's 20% less temperature in the incision."

Again, Dr Osher was discussing a proprietary tip that is due to become available shortly. "Normally I prefer a straight tip, but I've switched to this because the torsional technique needs some slope and it reduces temperatures."

He noted that there is no learning curve with microcoaxial phaco, however there is a learning curve for lens injection. "Once you learn the technique it is incredibly safe, effective and reliable," he said.

"It takes faith to get a lens through an un-enlarged 2.2 mm incision, but they offer stable chambers and reduction of turbulence that convinces me that this is the best operation available for my patients."

To prove his point, Dr Osher showed a video procedure of a patient with segmental iris dysgenesis. "There's no stroma, only pure pigment, which will be liberated in the chamber if there's any turbulence at all, and as you can see, there's no pigment liberated. What better demonstration of the gentleness of this procedure."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.